Progesterone has a major role in the development, differentiation and function of female reproductive tissues required for pregnancy, and recent clinical data indicate that progesterone increases breast cancer risk and may have a role in established breast cancer. The biological effects of progesterone are mediated by a progesterone receptor (PR) which is a member of the intracellular receptor superfamily of transcription factors; thus the major action of progesterone is thought to be a direct regulation of gene expression. The goal of the previously funded project was to define the molecular basis for how synthetic ligands, used to target and modulate PR activity, exhibit varying agonist and antagonist activities in a tissue/cell-type and gene specific manner. This is a relevant question with implications for development of improved selective ligand modulators of PR. Because the N terminal (AF-1) domain of PR is required for agonist activity of the partial antagonist RU486, as well as cell-type specific activities of PR, we sought to identify novel PR interacting proteins that mediate the activity of the N-terminal domain and consequently the activity of partial antagonists. We identified jun dimerization protein-2 (JDP-2) as such a factor and showed that it mediates AF-1 activity by a novel mechanism involving a cooperative interaction between the DNA binding domain and AF-1 of the receptor. We also unexpectedly identified a motif in the N-terminal domain of PR that interacts with SH3 domains of signaling molecules, most predominantly Src tyrosine kinases. This has led to the discovery that PR has another function as a rapid progesterone-dependent activator of Src/MAP-kinase signaling cascades through activation of Src by a specific SH3 domain displacement mechanism. This finding reveals a new paradigm for PR action independent of gene transcription. The present proposal seeks to continue studies on the role and mechanism of these two fundamentally different actions of PR with the following specific aims.
AIM#1 will determine the role of JDP-2 in PR-mediated gene transcription and regulation of selective ligand modulators of PR, and will define the mechanism of JDP-2 as a mediator of the AF-1 activity.
AIM#2 will further dissect PR activated cytoplasmic signaling pathways and by use of point mutations that dissociate cell signaling and transcriptional functions of PR, will evaluate the relative contribution of these two actions of PR to biological responses to progesterone in vitro and in vivo. These studies are anticipated to give new insights into the mechanism of action and role of progesterone in normal tissues and in breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK049030-10
Application #
6706995
Study Section
Endocrinology Study Section (END)
Program Officer
Margolis, Ronald N
Project Start
1994-09-30
Project End
2007-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
10
Fiscal Year
2004
Total Cost
$268,950
Indirect Cost
Name
University of Colorado Denver
Department
Pathology
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Elsarraj, Hanan S; Valdez, Kelli E; Hong, Yan et al. (2017) NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res 77:3802-3813
Grimm, Sandra L; Hartig, Sean M; Edwards, Dean P (2016) Progesterone Receptor Signaling Mechanisms. J Mol Biol 428:3831-49
TreviƱo, Lindsey S; Bolt, Michael J; Grimm, Sandra L et al. (2016) Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol 30:158-72
Simons Jr, S Stoney; Edwards, Dean P; Kumar, Raj (2014) Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges. Mol Endocrinol 28:173-82
Moore, Nicole L; Edwards, Dean P; Weigel, Nancy L (2014) Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells. J Steroid Biochem Mol Biol 144 Pt B:471-82
Obr, Alison E; Grimm, Sandra L; Bishop, Kathleen A et al. (2013) Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol 27:1808-24
Obr, Alison E; Edwards, Dean P (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357:4-17
Garza, Anna S; Khan, Shagufta H; Moure, Carmen M et al. (2011) Binding-folding induced regulation of AF1 transactivation domain of the glucocorticoid receptor by a cofactor that binds to its DNA binding domain. PLoS One 6:e25875
Wardell, Suzanne E; Narayanan, Ramesh; Weigel, Nancy L et al. (2010) Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Mol Endocrinol 24:335-45
Holley, Aaron K; Kiningham, Kelley K; Spitz, Douglas R et al. (2009) Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells. J Steroid Biochem Mol Biol 117:23-30

Showing the most recent 10 out of 28 publications